But the new top-line data from the REVEL trial has rewarded the patience of Lilly's leaders ... improvement in the primary endpoint of overall survival compared to the control arm of placebo ...

The study will continue to assess overall survival as a secondary endpoint, Lilly said. The data will ... and published simultaneously in the New England Journal of Medicine.

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Per Lilly, the above results demonstrate imlunestrant’s potential as a new oral endocrine therapy option for patients. Management continues to assess the secondary endpoint of overall survival ...